Your browser is no longer supported. Please, upgrade your browser.
Settings
ALDX Aldeyra Therapeutics, Inc. daily Stock Chart
ALDX [NASD]
Aldeyra Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.17 Insider Own2.90% Shs Outstand28.96M Perf Week8.56%
Market Cap148.71M Forward P/E- EPS next Y-2.49 Insider Trans17.91% Shs Float27.44M Perf Month-15.54%
Income-58.30M PEG- EPS next Q-0.72 Inst Own70.70% Short Float2.08% Perf Quarter-12.22%
Sales- P/S- EPS this Y-27.80% Inst Trans0.12% Short Ratio1.91 Perf Half Y-22.90%
Book/sh1.88 P/B2.73 EPS next Y-1.60% ROA-69.70% Target Price27.71 Perf Year-45.89%
Cash/sh2.63 P/C1.95 EPS next 5Y- ROE-82.30% 52W Range4.31 - 12.79 Perf YTD-38.13%
Dividend- P/FCF- EPS past 5Y-64.60% ROI- 52W High-59.85% Beta1.04
Dividend %- Quick Ratio6.40 Sales past 5Y- Gross Margin- 52W Low19.14% ATR0.48
Employees19 Current Ratio6.40 Sales Q/Q- Oper. Margin- RSI (14)42.22 Volatility6.09% 7.24%
OptionableYes Debt/Eq0.00 EPS Q/Q-33.90% Profit Margin- Rel Volume0.79 Prev Close5.32
ShortableYes LT Debt/Eq0.28 EarningsNov 07 BMO Payout- Avg Volume298.69K Price5.14
Recom1.60 SMA20-13.42% SMA50-11.54% SMA200-20.67% Volume235,459 Change-3.48%
Dec-04-18Initiated Citigroup Buy $23
Sep-26-18Reiterated Cantor Fitzgerald Overweight $23 → $30
Sep-13-18Initiated Janney Buy
Jan-26-18Initiated Seaport Global Securities Buy $13
Sep-26-16Initiated H.C. Wainwright Buy $18
Jul-01-16Initiated Stifel Buy $16
Jul-01-15Initiated Canaccord Genuity Buy $16
Mar-25-15Initiated Chardan Capital Markets Buy $16
Mar-20-15Reiterated H.C. Wainwright Buy $13 → $14
Nov-18-14Initiated H.C. Wainwright Buy $13
Jun-19-14Initiated Aegis Capital Buy $35
Dec-13-19 03:07PM  Hedge Funds Are Selling Aldeyra Therapeutics Inc (ALDX) Insider Monkey
Dec-10-19 05:42PM  Edited Transcript of ALDX earnings conference call or presentation 7-Nov-19 1:00pm GMT Thomson Reuters StreetEvents +5.81%
Dec-03-19 12:42PM  Investors question Lexington startup's dry eye treatment American City Business Journals -32.44%
07:59AM  The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial Benzinga
07:13AM  Aldeyra Therapeutics announces positive early results in trial of dry eye disease treatment MarketWatch
07:00AM  Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease Business Wire
Dec-02-19 04:01PM  Aldeyra Therapeutics to Host Conference Call and Webcast to Announce Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease Business Wire -6.14%
Nov-12-19 08:00AM  Aldeyra Therapeutics to Present at Upcoming Healthcare Investor Conferences Business Wire
Nov-07-19 07:00AM  Aldeyra Therapeutics Reports Third-Quarter 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones Business Wire
Nov-01-19 08:00AM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update Business Wire +5.01%
Oct-31-19 07:00AM  Aldeyra Therapeutics Releases Expanded Results from Allergen Chamber Trial and Announces Plans to Initiate the Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis Business Wire
Oct-30-19 04:01PM  Aldeyra Therapeutics to Host Conference Call and Webcast to Release Expanded Results from Allergen Chamber Trial and Announce Design of Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis Business Wire
Oct-21-19 08:02AM  Does The Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Share Price Fall With The Market? Simply Wall St.
Oct-13-19 04:33PM  The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings Benzinga
Oct-07-19 08:00AM  Aldeyra Therapeutics to Present at Ophthalmology Innovation Summit at American Academy of Ophthalmology 2019 Annual Meeting Business Wire
Sep-26-19 08:00AM  Aldeyra Therapeutics to Present Phase 3 ALLEVIATE Trial Results in Allergic Conjunctivitis at American Academy of Ophthalmology 2019 Annual Meeting Business Wire
Sep-25-19 09:50AM  7 Stocks the Insiders Are Buying on Sale InvestorPlace
08:00AM  Aldeyra Therapeutics to Present at 2019 Cantor Global Healthcare Conference Business Wire
Sep-24-19 08:00AM  Aldeyra Therapeutics Receives Fast Track Designation for ADX-2191 for the Prevention of Proliferative Vitreoretinopathy Business Wire
Sep-12-19 02:15AM  Aldeyra Therapeutics Inc (ALDX) President and CEO Todd C Brady Bought $102,800 of Shares GuruFocus.com
Sep-06-19 11:18AM  What Kind Of Shareholder Appears On The Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) Shareholder Register? Simply Wall St.
Aug-30-19 11:24PM  Edited Transcript of ALDX earnings conference call or presentation 8-Aug-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-28-19 08:30AM  Aldeyra Therapeutics to Participate in Upcoming Investor Conferences Business Wire
Aug-09-19 06:56PM  Aldeyra Therapeutics Inc (ALDX) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 07:00AM  Aldeyra Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update Business Wire
Jul-05-19 12:29PM  Heres What Hedge Funds Think About Aldeyra Therapeutics Inc (ALDX) Insider Monkey
Jun-25-19 09:26AM  No Solace For Aldeyra As Late-Stage Study Of Lead Drug In Anterior Uveitis Fails Benzinga -12.35%
07:39AM  Aldeyra shares slide 29% premarket after trial of eye disease treatment fails to meet goals MarketWatch
07:00AM  Aldeyra Therapeutics Announces Results from the SOLACE Trial in Noninfectious Anterior Uveitis Business Wire
Jun-24-19 04:30PM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the SOLACE Trial in Noninfectious Anterior Uveitis Business Wire
May-30-19 08:00AM  Aldeyra Therapeutics to Participate in the Jefferies 2019 Global Healthcare Conference PR Newswire
May-17-19 07:21PM  Edited Transcript of ALDX earnings conference call or presentation 9-May-19 12:00pm GMT Thomson Reuters StreetEvents
May-09-19 03:23PM  Aldeyra Therapeutics Inc (ALDX) Q1 2019 Earnings Call Transcript Motley Fool
07:00AM  Aldeyra Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update PR Newswire
May-02-19 08:00AM  Aldeyra Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019 PR Newswire
Apr-30-19 08:00AM  Aldeyra Therapeutics Announces Last Patient Dosed in the SOLACE Phase 3 Clinical Trial PR Newswire
Apr-09-19 08:00AM  Aldeyra Therapeutics Announces Presentation of Phase 2b Dry Eye Disease Results at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting PR Newswire
Apr-02-19 08:00AM  Aldeyra Therapeutics Announces First Patient Enrolled in the RENEW Phase 3 Clinical Trial for Dry Eye Disease PR Newswire
Mar-27-19 05:09PM  Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge Zacks
10:00AM  Future Brightens for 2 Small Biotech Stocks TheStreet.com
Mar-26-19 01:14PM  Here's Why Aldeyra Therapeutics Stock Soared as Much as 79.1% Today Motley Fool +35.99%
11:57AM  Aldeyra stock jumps 50 percent after eye allergy trial success American City Business Journals
10:37AM  Aldeyra's eye drug meets main goal in late-stage study, shares surge Reuters
09:41AM  Should Aldeyra Therapeutics (NASDAQ:ALDX) Be Disappointed With Their 68% Profit? Simply Wall St.
07:51AM  Alderya Therapeutics stock soars after conjunctivitis treatment trial meets key endpoints MarketWatch
07:46AM  Aldeyra's eye drug meets main goal in late-stage study, shares surge Reuters
07:00AM  Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis PR Newswire
Mar-25-19 04:01PM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis PR Newswire
Mar-13-19 10:35AM  Options Traders Expect Huge Moves in Aldeyra (ALDX) Stock Zacks +5.50%
02:02AM  Edited Transcript of ALDX earnings conference call or presentation 8-Mar-19 1:00pm GMT Thomson Reuters StreetEvents
Mar-08-19 12:12PM  Aldeyra Therapeutics Inc (ALDX) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:00AM  Aldeyra Therapeutics Announces Year-End 2018 Financial Results PR Newswire
Mar-01-19 08:00AM  Aldeyra Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Friday, March 8, 2019 PR Newswire
Feb-28-19 07:00AM  Aldeyra Therapeutics Provides Update on Ophthalmic Programs at 2019 Research & Development Day PR Newswire
Feb-12-19 08:00AM  Aldeyra Therapeutics to Host 2019 Research & Development Day PR Newswire
Jan-30-19 07:55AM  Research Report Identifies Cameco, American Equity Investment Life Holding, AG Mortgage Investment Trust, Arena Pharmaceuticals, Mimecast, and Aldeyra Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Jan-29-19 08:00AM  Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision PR Newswire
Jan-15-19 08:00AM  Aldeyra Therapeutics Announces Promotion of Stephen G. Machatha, Ph.D. to Position of Senior Vice President of Technical Operations PR Newswire
Jan-03-19 08:00AM  Aldeyra Therapeutics Announces Promotion of David McMullin to Position of Chief Commercial Officer PR Newswire
Dec-20-18 10:33AM  Edited Transcript of ALDX earnings conference call or presentation 14-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
08:00AM  Aldeyra Therapeutics Announces Last Patient Dosed in the ALLEVIATE Phase 3 Clinical Trial PR Newswire
Dec-17-18 09:42PM  Should You Buy Aldeyra Therapeutics Inc (ALDX)? Insider Monkey -6.77%
Nov-30-18 12:48PM  Should You Be Concerned About Aldeyra Therapeutics Incs (NASDAQ:ALDX) Historical Volatility? Simply Wall St.
Nov-28-18 08:00AM  Aldeyra Therapeutics to Participate at Citi's 2018 Global Healthcare Conference PR Newswire
Nov-14-18 07:00AM  Aldeyra Therapeutics Announces Third Quarter 2018 Financial Results PR Newswire -11.50%
Nov-08-18 08:35AM  Recent Analysis Shows Freightcar America, Anworth Mortgage Asset, AMN Healthcare Services, Cenovus Energy, Dynex Capital, and Aldeyra Therapeutics Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-06-18 08:00AM  Aldeyra Therapeutics to Present at the 2018 Stifel Healthcare Conference PR Newswire
Nov-05-18 08:00AM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2018 Financial Results PR Newswire
Oct-16-18 02:46PM  Research Report Identifies Aldeyra Therapeutics, AAON, Douglas Dynamics, Insmed, Northern Oil and Gas, and SMART Global with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-02-18 09:32AM  Mangrove Partners: Performance, AUM, and Holdings Insider Monkey
Sep-28-18 10:06AM  Aldeyra Therapeutics (ALDX) Looks Good: Stock Adds 7.5% in Session Zacks
08:00AM  Aldeyra Therapeutics to Present at the 2018 Cantor Global Healthcare Conference PR Newswire
Sep-27-18 08:00PM  Aldeyra Therapeutics, Inc. Announces Public Offering of Common Stock PR Newswire +7.49%
09:12AM  Aldeyra Surges on Positive Dry Eye Study Data on Reproxalap Zacks
08:20AM  The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron Benzinga
08:00AM  Todays Research Reports on Stocks to Watch: Aldeyra Therapeutics and Alexion Pharmaceuticals ACCESSWIRE
Sep-26-18 04:01PM  Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock PR Newswire +34.85%
12:54PM  Aldeyra Therapeutics Stock Skyrockets on Dry Eye Study Results InvestorPlace
08:25AM  The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial Benzinga
08:12AM  Alderya's stock rockets after positive trial results of mesothelioma treatment MarketWatch
07:00AM  Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trial PR Newswire
Sep-25-18 04:30PM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Results from Phase 2b Dry Eye Disease Clinical Trial PR Newswire
08:00AM  Aldeyra Therapeutics Announces Positive Mesothelioma Investigator-Sponsored Clinical Trial Results Presented at The International Association for The Study of Lung Cancer 19th World Conference on Lung Cancer PR Newswire
Sep-06-18 08:52AM  Implied Volatility Surging for Aldeyra Therapeutics (ALDX) Stock Options Zacks
Aug-17-18 08:20AM  Consolidated Research: 2018 Summary Expectations for PDF Solutions, MYOS RENS Technology, Aldeyra Therapeutics, The Ensign Group, Everi, and Ardelyx Fundamental Analysis, Key Performance Indications GlobeNewswire
Aug-09-18 07:30AM  Aldeyra Therapeutics Announces Second Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
06:00AM  Aldeyra Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 08:00AM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2018 Financial Results and Corporate Update PR Newswire
Aug-01-18 08:00AM  Aldeyra Therapeutics to Present at the 38th Annual Canaccord Genuity Growth Conference PR Newswire
Jul-31-18 08:00AM  Aldeyra Therapeutics Appoints Joshua Reed as Chief Financial Officer PR Newswire
Jul-24-18 08:00AM  Aldeyra Therapeutics Announces First Patient Enrolled in Sjögren-Larsson Syndrome Pivotal Phase 3 Clinical Trial PR Newswire
Jul-12-18 08:00AM  Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2b Clinical Trial PR Newswire
Jun-26-18 08:00AM  Aldeyra Therapeutics Announces Development Programs at 2018 Research Day PR Newswire
Jun-25-18 04:01PM  Aldeyra Therapeutics Joins the Russell 3000® and 2000® Indexes PR Newswire
Jun-20-18 08:00AM  Aldeyra Therapeutics Announces 2018 Research Day PR Newswire
May-30-18 07:45AM  Analysis: Positioning to Benefit within Aldeyra Therapeutics, Freightcar America, Bank of Hawaii, Heritage-Crystal Clean, Amedisys, and U.S. Global Investors Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
May-15-18 07:30AM  Aldeyra Therapeutics Announces First Quarter 2018 Financial Results PR Newswire
06:00AM  Aldeyra Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-10-18 08:00AM  Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy PR Newswire
May-09-18 08:00AM  Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First Quarter 2018 Financial Results PR Newswire
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase IIb clinical trial for the treatment of dry eye diseases, as well as Phase III clinical trial for the treatment of allergic conjunctivitis, noninfectious anterior uveitis, and Sjogren-Larsson syndrome. Its portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative inflammatory diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, as well as ADX-103 for the treatment of retinal diseases. In addition, the company develops ADX-2191, an intravitreal dihydrofolate reductase inhibitor for the prevention of proliferative vitreoretinopathy, a sight-threatening retinal disease; and ADX-1615, which inhibits Hsp90 for the treatment of various inflammatory diseases. Aldeyra Therapeutics, Inc. has a partnership with Janssen, a Johnson & Johnson company to develop RASP for systemic inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brady Todd CPresident and CEOSep 30Buy5.688,71049,483632,216Oct 02 07:36 AM
Brady Todd CPresident and CEOSep 23Buy5.818,68050,433623,506Sep 25 07:40 AM
Brady Todd CPresident and CEOSep 18Buy5.9114,28884,465614,826Sep 20 07:37 AM
Bronstein BenDirectorSep 17Buy5.851,7009,94518,644Sep 19 04:23 PM
Brady Todd CPresident and CEOSep 16Buy6.033,00018,090591,991Sep 17 07:35 AM
DOUGLAS RICHARDDirectorSep 13Buy6.005,00030,00085,000Sep 17 07:36 AM
Brady Todd CPresident and CEOSep 13Buy5.7910,00057,900588,991Sep 17 07:35 AM
DOUGLAS RICHARDDirectorSep 12Buy6.0310,00060,27680,000Sep 13 07:54 AM
JOYCE MARTIN JOSEPHDirectorSep 12Buy5.861,7009,96419,644Sep 16 04:15 PM
DOUGLAS RICHARDDirectorSep 11Buy5.7510,00057,52970,000Sep 13 07:54 AM
DOUGLAS RICHARDDirectorSep 10Buy5.0910,00050,85760,000Sep 11 04:05 PM
Brady Todd CPresident and CEOSep 10Buy5.3910,00053,937578,991Sep 11 04:05 PM
DOUGLAS RICHARDDirectorSep 09Buy4.9110,00049,10650,000Sep 11 04:05 PM
Brady Todd CPresident and CEOSep 09Buy4.8910,00048,887568,991Sep 11 04:05 PM
Clark David JChief Medical OfficerSep 06Buy5.065,00025,31117,878Sep 10 05:01 PM
Reed JoshuaChief Financial OfficerSep 05Buy4.713,20015,07235,774Sep 09 04:38 PM
McMullin DavidChief Commerical OfficerSep 05Buy4.684,32920,2606,148Sep 09 04:37 PM
TREU JESSE IDirectorMar 26Sale10.0196,743968,3978,763Mar 28 05:10 PM